% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

ieteriinto 2 posts  |  Last Activity: Nov 24, 2015 4:11 PM Member since: Mar 20, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • ieteriinto by ieteriinto Nov 24, 2015 4:11 PM Flag

    this drug has as much potential as any in alzheimers its bryostatin.

  • ieteriinto by ieteriinto Nov 9, 2015 8:12 PM Flag

    Progenics’ Small Molecule Diagnostic 1404

    Progenics’ molecular imaging radiopharmaceutical product candidate 1404 targets the extracellular domain of prostate specific membrane antigen (PSMA), a protein amplified on the surface of 95% of prostate cancer cells and a validated target for the detection of primary and metastatic prostate cancer. 1404 is labeled with technetium-99m, a gamma-emitter isotope that is widely available, relatively inexpensive, facilitates efficient preparation, and has spectrum characteristics attractive for nuclear medicine imaging applications.

    Azedra is a late-stage ultra-orphan candidate being developed for the treatment of malignant pheochromocytoma and paraganglioma. Clinical testing is being conducted under a Special Protocol Assessment which may accelerate FDA review and marketing approval decisions.

2.19-0.01(-0.45%)Nov 25 3:59 PMEST